gm dry eye going into phase 3. Commercialization in 2015
GET THIS SHIT IN CLINICAL TRIALS MAN- 5 DOLLAR A SHARE LOW FLOATER
New Report: Thymosin ß4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice
Date : 07/15/2014 @ 9:00AM
Source : Business Wire
Stock : Regenerx Biopharmaceuticals, Inc. (QB) (RGRX)
Quote : 0.175 0.0 (0.00%) @ 7:18AM
New Report: Thymosin ß4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice
Print
Alert
Regenerx Biopharmaceuticals, Inc. (QB) (USOTC:RGRX)
Historical Stock Chart
1 Month : From Jun 2014 to Jul 2014
Click Here for more Regenerx Biopharmaceuticals, Inc. (QB) Charts.
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that a new paper entitled, Thymosin ß4 Prevents Cardiac Rupture and Improves Cardiac Function in Mice with Myocardial Infarction, was published in the journal, Heart Circulation Physiology, on July 11, 2014. “The present study shows for the first time that 1) Tß4 is able to reduce incidence of cardiac rupture post-MI [myocardial infarction or heart attack] and markedly improved cardiac function at 5 weeks after MI, and that 2) the cardiac protective effects of Tß4 after MI were associated with a significant reduction of excessive inflammatory response and cardiomyocyte apoptosis as well as with an enhancement of angiogenesis. From a clinical point of view, Tß4 could potentially be a therapeutic candidate for patients with acute MI,” according to the study’s authors.
Animals were treated with Tß4 daily at a relatively low dose for 7 days using a minipump implant. Treatment with Tß4 ameliorated left ventricular dilation, improved cardiac function, and not only decreased the mortality rate due to cardiac rupture but also significantly improved cardiac function after MI.
The study received funding from the Henry Ford Health System and the National Institutes of Health. RegeneRx Biopharmaceuticals Inc. provided the Tß4 under a Material Transfer Agreement.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin ß4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the EU, and has an extensive worldwide patent portfolio covering its products. Recently, RGN-259, the Company’s ophthalmic drug candidate has been designated as an orphan drug for the treatment of neurotrophic keratopathy, which is the primary focus of RegeneRx’s clinical development efforts in the U.S. For additional information about RegeneRx please visit www.regenerx.com
Forward-Looking Statements
Market Data 
Markets 
AI
